Bifidobacterium spp: the promising Trojan Horse in the era of precision oncology.

Abstract

Selective delivery of therapeutic agents into solid tumors has been a major challenge impeding the achievement of long-term disease remission and cure. The need to develop alternative drug delivery routes to achieve higher drug concentration in tumor tissue, reduce unwanted off-target side effects and thus achieve greater therapeutic efficacy, has resulted in an explosive body of research. Bifidobacterium spp. are anaerobic, nonpathogenic, Gram-positive bacteria, commensal to the human gut that are a possible anticancer drug-delivery vehicle. In this review, we describe Bifidobacterium's microbiology, current clinical applications, overview of the preclinical work investigating Bifidobacterium's potential to deliver anticancer therapy, and review the different strategies used up to date. Finally, we discuss both current challenges and future prospects.

• Authors: Nealie Ngo, Khalil Choucair, Justin F Creeden, Hanan Qaqish, Krupa Bhavsar, Chantal Murphy, Kendra Lian, Mary T Albrethsen, Laura Stanbery, Richard C Phinney, F Charles Brunicardi, Lance Dworkin, John Nemunaitis
• Journal: Future oncology (London, England) (Future Oncol) Vol. 15 Issue 33 Pg. 3861-3876 (Nov 2019) ISSN: 1744-8301 [Electronic] England
• PMID: 31668087 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents

Topics

• Animals
• Antineoplastic Agents (administration & dosage)
• Bifidobacterium (physiology)
• Clinical Trials as Topic
• Disease Models, Animal
• Drug Delivery Systems (methods)
• Drug Evaluation, Preclinical
• Genes, Reporter (genetics)
• Genetic Therapy (methods)
• Genetic Vectors (administration & dosage, genetics)
• Humans
• Immunotherapy (methods)
• Medical Oncology (methods, trends)
• Neoplasms (genetics, immunology, therapy)
• Plasmids (genetics)
• Precision Medicine (methods, trends)
• Probiotics (administration & dosage)
• Treatment Outcome